Kato Naoya, Muroyama Ryosuke, Goto Kaku
Unit of Disease Control Genome Medicine, The Institute of Medical Science, The University of Tokyo.
Nihon Rinsho. 2012 Apr;70(4):664-70.
Recently, first direct acting antiviral (DAA) against hepatitis C virus (HCV) has just approved in Japan. It is a first generation protease inhibitor, telaprevir. Telaprevir inhibits HCV NS3 & 4A serine protease, and combination with pegylated-interferon and ribavirin has now become a standard of care (SOC) for patients with genotype 1 high viral load hepatitis C. Fortunately, more than 50 new antivirals against HCV are under development including antivirals in preclinical trials. New antivirals are classified into several categories; (1) NS3 & 4A protease inhibitor, (2) NS5B polymerase inhibitor, (3) NS5A inhibitor, (4) host factor targeting antivirals, (5) interferon-related antivirals, and others. Combination of different classes of antivirals without interferon is expected to become a future SOC for hepatitis C.
最近,日本刚刚批准了首个针对丙型肝炎病毒(HCV)的直接作用抗病毒药物(DAA)。它是第一代蛋白酶抑制剂特拉匹韦。特拉匹韦可抑制HCV NS3和4A丝氨酸蛋白酶,与聚乙二醇化干扰素和利巴韦林联合使用现已成为1型高病毒载量丙型肝炎患者的标准治疗方案(SOC)。幸运的是,目前正在研发50多种新型抗HCV药物,包括处于临床前试验阶段的抗病毒药物。新型抗病毒药物分为几类:(1)NS3和4A蛋白酶抑制剂,(2)NS5B聚合酶抑制剂,(3)NS5A抑制剂,(4)靶向宿主因子的抗病毒药物,(5)干扰素相关抗病毒药物等。预计不含干扰素的不同类别抗病毒药物联合使用将成为未来丙型肝炎的标准治疗方案。